Responses
Original research
Clinical trials
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 23 November 2015
- Published on: 23 November 2015Myocardial reduction of Gb3 content in Anderson-Fabry diseaseShow More
Dear Editor,
We read with interest the study by Hughes et al (1) that for the first time showed a reduction of Gb3 content in endomyocardial biopsy tissue of patients with Fabry cardiomyopathy after six months agalsidase alfa treatment.
However, it should be point out that this study doesn’t demonstrate the efficacy of enzyme replacement therapy in clearing the Gb3 deposits from the cardiomyocytes, that i...
Conflict of Interest:
None declared.